| Literature DB >> 24489902 |
Christopher Rentsch1, Ionut Bebu2, Jodie L Guest3, David Rimland4, Brian K Agan2, Vincent Marconi3.
Abstract
BACKGROUND: Variable selection is an important step in building a multivariate regression model for which several methods and statistical packages are available. A comprehensive approach for variable selection in complex multivariate regression analyses within HIV cohorts is explored by utilizing both epidemiological and biostatistical procedures.Entities:
Mesh:
Year: 2014 PMID: 24489902 PMCID: PMC3906149 DOI: 10.1371/journal.pone.0087352
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Comparing Subset Models to a Full Model in Order to Detect a Potential Parsimonious Model.
Top panel title: AIC Weights and Evidence Ratios for Stepwise Selections of Covariates Into a Full Model, Based on AIC Values. Bottom panel title: Score and AIC Values for Stepwise Selections of Covariates Into a Full Model, Based on Score Values. Note: Areas shaded to the right of the circle-dotted line denotes variables that were included in the full model but deemed unnecessary for a parsimonious model.
Figure 2Models Considered by Bayesian Model Averaging, in Order of Posterior Probability.
Variables Positively (Negatively) Associated With Outcome are in Grey (Black).
Comparison of All-Cause Mortality Cox Regression Models Between NHS and HAVACS Patients Based on Three Approaches: Hypothesis-Testing, Information-Theory, And Bayesian Model Averaging, 1996 – 2010, n = 1,727.
| Hypothesis-testing | Information-theory | Bayesian model averaging | |||||||
| "Full" model | "Parsimonious" model | Posterior | Conditional posterior | ||||||
| Covariate | HR | 95% CI | HR | 95% CI | Selected (%) | HR | 95% CI | HR | 95% CI |
| Cohort, NHS vs. HAVACS |
|
|
|
|
|
|
|
|
|
|
| |||||||||
| Age at HAART initiation |
|
|
|
|
|
|
|
|
|
| Sex, female vs. male | 2.64 | 0.64, 10.80 | 2.58 | 0.63, 10.55 | 14.1% | 1.14 | 0.50, 2.64 | 2.60 | 0.64, 10.59 |
| Race, AA vs. other | 1.20 | 0.80, 1.79 | – | 4.3% | 1.00 | 0.91, 1.11 | 1.16 | 0.79, 1.74 | |
|
| |||||||||
| HIV diagnosis to HAART initiation | 1.00 | 0.99, 1.01 | – | 3.2% | 1.00 | 1.00, 1.00 | 1.00 | 0.99, 1.01 | |
| Viral load at HAART initiation, log copies/mL | 9.8% | ||||||||
|
| 0.46 | 0.19, 1.15 | 0.47 | 0.19, 1.15 | 0.93 | 0.55, 1.57 | 0.46 | 0.08, 2.87 | |
|
| 1.46 | 0.91, 2.33 | 1.46 | 0.91, 2.33 | 1.04 | 1.01, 1.36 | 1.48 | 0.27, 8.25 | |
|
| ref | ref | ref | ref | |||||
| CD4 at HAART initiation, cells/mL | 85.0% | ||||||||
|
| 1.28 | 0.79, 2.07 | 1.30 | 0.82, 2.06 | 1.36 | 0.84, 2.20 | 1.43 | 0.45, 4.60 | |
|
| 0.60 | 0.34, 1.03 | 0.61 | 0.35, 1.05 | 0.69 | 0.38, 1.24 | 0.64 | 0.19, 2.26 | |
|
| ref | ref | ref | ref | |||||
| Previous AIDS-defining illness | 0.95 | 0.62, 1.43 | – | 3.4% | 1.00 | 0.92, 1.08 | 0.92 | 0.61, 1.39 | |
| Chronic hepatitis B co-infection |
|
|
|
| 44.5% | 1.33 | 0.65, 2.73 | 1.90 | 1.10, 3.26 |
| Hepatitis C co-infection |
|
|
|
| 49.0% | 1.24 | 0.75, 2.06 | 1.55 | 1.06, 3.26 |
| Previous antiretroviral use | 1.40 | 0.95, 2.07 | 1.33 | 0.93, 1.92 | 23.6% | 1.08 | 0.78, 1.49 | 1.38 | 0.96, 1.98 |
|
| 0.0% | ||||||||
| Non-nucleoside reverse transcriptase inhibitor | ref | ref | |||||||
| Boosted protease inhibitor |
|
|
|
| |||||
| Unboosted protease inhibitor | 1.28 | 0.86, 1.90 | 1.29 | 0.87, 1.91 | |||||
| Other | 0.72 | 0.25, 2.01 | 0.71 | 0.25, 1.99 | |||||
Abbreviations: AA - African -American/Black ; AIDS – acquired immune deficiency syndrome; CD4 – cluster of differentiation 4; CI – confidence interval; HAART - Highly Active Antiretroviral Therapy; HAVACS - HIV Atlanta VA Cohort Study; HR – hazard ratio; NHS - US Military HIV Natural History Study; ref – referent group.
Notes: Bold hazard ratios and 95% confidence intervals are significant at the P<0.05 level.
1993 definition, exclusive of CD4<200.